Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation during intraday trading. The surge follows commercial success for the company’s obesity and diabetes drugs, which have driven revenue and investor expectations. Market moves reflect how high-margin chronic-disease therapies can reshape firm valuations across the drug sector.